24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
NINDALIEVA 150MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | NINDALIEVA 150MG |
|---|---|
| Composition | Nintedanib Softgelatin Capsules 150mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Strip (3 x 10) |
| Country of Origin | India |
Nintedanib Softgelatin Capsules 150mg (Nintedanib Softgelatin Capsules 150mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
NINDALIEVA 150 MG (Nintedanib Softgelatin Capsules 150 mg) is a prescription medicine used for the treatment of Idiopathic Pulmonary Fibrosis (IPF), Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), and certain other chronic lung conditions as prescribed by healthcare professionals. It contains Nintedanib 150 mg, a tyrosine kinase inhibitor that helps slow the progression of lung fibrosis by targeting multiple pathways involved in tissue scarring and abnormal cell growth.
Idiopathic Pulmonary Fibrosis is a serious chronic lung disease characterized by progressive scarring of lung tissue. Over time, this scarring reduces the lungs' ability to transfer oxygen into the bloodstream, making breathing increasingly difficult. NINDALIEVA 150 MG helps slow the rate of lung function decline, supporting long-term respiratory health and improving disease management.
Nintedanib works by blocking specific growth factor receptors involved in the formation of fibrotic tissue. By inhibiting these pathways, the medicine helps reduce excessive scar tissue development in the lungs and may delay disease progression in eligible patients.
In addition to pulmonary fibrosis, Nintedanib is also used in selected patients with other progressive interstitial lung diseases and may be prescribed as part of comprehensive respiratory care programs.
NINDALIEVA 150 MG is commonly prescribed for:
• Idiopathic Pulmonary Fibrosis (IPF)
• Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
• Chronic Progressive Lung Fibrosis
• Long-Term Pulmonary Disease Management
• Specialist Respiratory Care Programs
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in respiratory medicine.
Patients receiving Nintedanib therapy may require regular monitoring of liver function, lung function, overall treatment response, and routine medical assessments. These evaluations help healthcare providers optimize treatment outcomes and identify potential side effects early.
Due to its effectiveness in slowing disease progression and supporting long-term respiratory care, NINDALIEVA 150 MG has become an important treatment option in modern pulmonary medicine.
NINDALIEVA 150 MG (Nintedanib Softgelatin Capsules 150 mg) is primarily used for the treatment and management of chronic fibrotic lung diseases.
The medicine is widely used to slow the progression of idiopathic pulmonary fibrosis and preserve lung function.
Doctors may prescribe Nintedanib for patients with chronic fibrosing lung diseases that continue to worsen over time.
The medicine helps manage lung involvement associated with systemic sclerosis.
NINDALIEVA supports ongoing treatment strategies for chronic lung fibrosis.
The medicine is often included in specialist respiratory treatment protocols.
Nintedanib helps reduce the rate at which lung capacity decreases in progressive fibrotic diseases.
Nintedanib belongs to a class of medicines known as tyrosine kinase inhibitors.
NINDALIEVA works by:
• Blocking multiple growth factor receptors
• Reducing abnormal tissue scarring
• Slowing fibrotic lung disease progression
• Helping preserve lung function
• Limiting excessive connective tissue formation
• Supporting long-term respiratory health
This targeted mechanism helps reduce the progression of fibrosis and supports better disease management.
Like all prescription medicines, NINDALIEVA 150 MG may cause side effects in some patients. The frequency and severity of side effects vary depending on individual health conditions and treatment duration.
Diarrhea is one of the most frequently reported side effects of Nintedanib therapy.
Patients may experience mild to moderate nausea during treatment.
Some individuals may develop episodes of vomiting.
Stomach discomfort or abdominal pain may occur.
Reduced appetite may be experienced during treatment.
Gradual weight loss may occur in certain patients.
Weakness, tiredness, or low energy levels may develop.
Changes in liver function test results may be observed.
Some patients may experience mild headaches during therapy.
Seek immediate medical attention if you experience:
• Severe abdominal pain
• Significant bleeding
• Yellowing of the skin or eyes
• Severe liver-related symptoms
• Chest pain
• Severe allergic reactions
• Persistent vomiting
• Severe dehydration
• Difficulty breathing
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of NINDALIEVA 150 MG (Nintedanib Softgelatin Capsules 150 mg) should always be determined by a qualified healthcare professional.
Treatment requirements may vary depending on the diagnosed condition.
Patients with liver impairment may require careful monitoring and dosage adjustments.
Age, body weight, and general health status may influence treatment planning.
Doctors may adjust therapy based on effectiveness and tolerability.
Dosage modifications may be required if significant side effects occur.
• Take the capsule exactly as prescribed.
• Swallow the capsule whole with water.
• Do not crush, chew, or open the capsule.
• Take the medicine with food if recommended by your healthcare provider.
• Follow the prescribed treatment schedule carefully.
• Do not stop treatment without consulting your doctor.
Regular monitoring is essential throughout therapy.
Before starting treatment, patients should inform their doctor if they have:
• Liver disease
• Bleeding disorders
• Heart disease
• Digestive disorders
• Previous allergic reactions to medications
• Any serious chronic medical conditions
Patients should also disclose all prescription medicines, supplements, and herbal products currently being used to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
• Store in a cool and dry place.
• Protect from direct sunlight and moisture.
• Keep out of reach of children.
• Store at recommended room temperature.
• Trusted Nintedanib formulation
• Effective pulmonary fibrosis management
• Helps slow disease progression
• Supports long-term respiratory health
• Manufactured under strict pharmaceutical quality standards
• Reliable treatment option for chronic fibrotic lung diseases
• Suitable for modern pulmonary care protocols
It is primarily used for the treatment of idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung diseases, and systemic sclerosis-associated interstitial lung disease.
Nintedanib is a tyrosine kinase inhibitor that helps slow the progression of fibrotic lung diseases.
No, it does not cure pulmonary fibrosis, but it may help slow disease progression and preserve lung function.
No, Nintedanib is not a steroid. It is a targeted antifibrotic medicine.
Yes, diarrhea is one of the most common side effects and should be reported to your healthcare provider if severe.
Yes, doctors typically recommend liver function tests, lung function assessments, and routine medical evaluations.
No, treatment should only be modified or discontinued under medical supervision.
Yes, this medicine should always be used under the guidance of qualified healthcare professionals experienced in respiratory medicine and pulmonary disease management.